Trials / Conditions / Untreated Metastatic Squamous Neck Cancer With Occult Primary

Untreated Metastatic Squamous Neck Cancer With Occult Primary

14 registered clinical trials studyying Untreated Metastatic Squamous Neck Cancer With Occult Primary.

Status	Trial	Sponsor	Phase
Completed	Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV No NCT02245100	Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University	—
Completed	Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell C NCT02035527	Ohio State University Comprehensive Cancer Center	Phase 1
Completed	Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurr NCT01316757	Fox Chase Cancer Center	Phase 2
Completed	Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab NCT00939627	National Cancer Institute (NCI)	Phase 2
Terminated	Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous C NCT00906360	National Cancer Institute (NCI)	Phase 1
Completed	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer NCT00096512	National Cancer Institute (NCI)	Phase 2
Completed	Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer NCT00098631	National Cancer Institute (NCI)	Phase 2
Completed	Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362	National Cancer Institute (NCI)	Phase 1
Completed	Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497	National Cancer Institute (NCI)	N/A
Completed	Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer NCT00049283	National Cancer Institute (NCI)	Phase 1
Completed	Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498	National Cancer Institute (NCI)	Phase 1
Completed	7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681	National Cancer Institute (NCI)	Phase 1
Completed	Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and NCT00023959	National Cancer Institute (NCI)	Phase 1